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Progressive multifocal leukoencephalopathy (PML) is a neurological disease caused by infection of the central nervous system 
(CNS) with the JC polyomavirus (JCV). JCV is endemic and infects a large proportion (70–90%) of healthy individuals worldwide, 
but infection is latent. JCV reactivation may occur, if the immune function is compromised. Aim: To present a PML case in a CLL 
patient after a long course of disease and treatment with fludarabine. JCV virus infection in this patient was proven both in brain 
biopsy material and blood. Methods: Patient with a nine-year history of CLL was hospitalized with the weakness in the right leg 
and left hand, tremors, speech difficulties. An MRI diagnosed infiltrative glial tumor of the left hemisphere, proliferating pre-
dominantly in the frontal lobe, more in the gyrus frontalis superior region. CNS tumor biopsy performed. Results: Morphology and 
immunoprofile of the lesion consistent with progressive multifocal leukoencephalopathy. The material from biopsy was diagnosed 
as positive for JCV DNA. JCV and HHV-7 genomic sequences were found in patient’s PBL DNA sample. In a plasma DNA sample, 
only genomic sequences were detected. Conclusion: The present case draws attention to the fact that the use of fludarabine and its 
combinations in CLL therapy increases the risk of JCV infection reactivation and development of serious complications like PML.
Key Words: progressive multifocal leukoencephalopathy, JC polyomavirus, chronic lymphocytic leukemia, fludarabine, immuno-
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Progressive multifocal leukoencephalopathy �PML� 
is a neurological disease caused �y infection of the 
central nervous system �CNS� with the JC polyomavi-
rus �JCV�. JCV was discovered in ��7� and is a type 
of human polyomavirus genetically similar to the 
BK virus. JCV is endemic and infects a large proportion 
�7����%� of healthy individuals worldwide [�]� �ut 
infection is latent. Following primary infection� the virus 
esta�lishes a latent infection which may persist in a la-
tent state for an extended period� even in immuno-
competent individuals. JCV reactivation� however� may 
occur� if the immune function is compromised� for 
example� in HIV-infected patients� patients receiving 
�one marrow or renal transplants and patients receiv-
ing chemotherapy [�]. �uring the course of AI�S� 
up to �% of patients may develop PML. For hemato-
logical patients the risk of developing PML is lower and 
incidence of PML in previously descri�ed chronic 
lymphocytic leukemia �CLL� patients is �.5�% [�]. Ir-
radiation of the CNS� intrathecal application of metho-
trexate� and severe immunosuppression are risk-in-
creasing factors. If JCV activation occurs� the virus can 
cause demyelinization� �eginning in the deeper �rain 
structures and progressing rapidly [�]. PML clinical 
features are fatigue� disorientation� dementia� depres-
sion� seizures� hemiparalysis� and other focal neuro-
logical signs. In most cases� the disease has a fatal 
course within weeks or months.
Immunosuppression also develops in cases 
of CLL� especially following fludara�ine therapy. Here� 
we present a PML case in a CLL patient after a long 
course of disease and treatment with fludara�ine. JCV 
virus infection in this patient was proven �oth in �rain 
�iopsy material and �lood.
MATERIALS AND METHODS
In March ����� a 5�-year-old man was diagnosed 
with CLL. He himself detected enlarged lymphatic 
nodes in the neck and consulted his family doctor. 
At that stage: WBC — ��.� × ���/l� HGB — ��� g/l� 
RBC — �.�5 × ����/l� lym — ��.� × ���/l� PLT — 
�66 × ���/l� small peripheral lymphadenopathy� CLL 
stage II diagnosed according to Binet. For eight years 
he received chloram�ucil and prednisolone therapy 
as out-patient� without achieving hematological remis-
sion. Because of disease progression received � cy-
cles of COP �cyclophosphani� vincristini� prednisoloni�� 
followed �y 7 cycles FM� �fludara�ine� mitoxantrone� 
dexamethasone�. 
In Fe�ruary ���8� patient with a nine-year history 
of CLL was hospitalized in a surgical ward for an unre-
lated condition and reported a three week history of the 
weakness in the right leg and left hand� tremors. The 
patient also experienced speech difficulties� including 
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clumsiness and a slight slur. The neurologist’s final 
conclusion was cortinuclear failure of the right side with 
central paresis of the left arm with tremor� central paresis 
of the right leg� and motor aphasia. An MRI diagnosed 
infiltrative glial tumor of the left hemisphere� proliferat-
ing predominantly in the frontal lo�e� more in the gyrus 
frontalis superior region. The process was spreading 
to the frontal part of corpus callosum and putamen� and 
also the temporal lo�e of the same hemisphere. Se-
veral tiny periventricular and hyperintense su�cortical 
vascular foci of the same nature in �oth hemispheres. 
Blood count: WBC — �.� × ���/l� HGB — ��� g/L� RBC — 
�.5� × ����/l� PLT — ��� × ���/l� lym — �.�� × ���/l. 
Biochemical analyses without pathology� only L�H and 
�eta�-microglo�ulin increased. Additional tests: Anti 
HIV�/� — negative� EBV �NA — negative� CMV �NA 
qualitatively — negative� Aspergillus Ag quantitatively — 
negative� Cryptococcus Ag — negative.
In March ���8� he was transferred to the neuro-
surgery ward. Patient was recum�ent� partial aphasia� 
hemisyndrome of the left side. Frontal lo�e cere�rot-
omy was performed and tissue samples taken for his-
tological examination. CNS tumor �iopsy performed.
RESULTS
Morphology and immunoprofile of the lesion con-
sistent with progressive multifocal leukoencephalopa-
thy �Figure�.
Figure. Scattered throughout the hypercellular lesion with nu-
merous foamy macrophages and reactive astrocytes there are 
homogenous intranuclear inclusions in oligodendrocytes with 
simultaneous ground glass appearance of nuclei �H&E × ���
The material was additionally examined to detect 
JCV �NA. �NA was extracted from ��7 µm-thick 
sections o�tained from formalin-fixed and paraffin 
em�edded �rain tissue. Sections were digested with 
protease K and �NA was purified on silica columns 
�Qiagen Gm�H� Germany� according to the manu-
facturer’s protocol. The technique consisted of ge-
nomic amplification �nested PCR with JC�/JC� primers 
in external amplification and PEP�/PEP� in internal 
amplification� followed �y restriction fragment length 
polymorphism with the enzyme BamH�. Beta-glo�in 
gene was used as a control for the integrity of the 
genome of the sample. After amplification with the 
primers� a �7� �p fragment of the JCV genome was 
o�tained. This fragment was digested with the enzyme 
BamH�. The reaction mixture was electrophoresed 
on a �% agarose gel. The viral su�type was determined 
according to the digestion �ands as descri�ed previ-
ously [��.]. After digestion with the enzyme BamH� the 
�7� p� �and disappeared and the case was diagnosed 
as positive for JCV �NA.
JCV was detected in the patient’s �lood. The 
nested polymerase chain reaction �nPCR� was used 
for the detection of viral sequences in �NA isolated 
from peripheral �lood leukocytes �PBL� and plasma 
�markers of latent/persistent and active infection� 
respectively�. JCV and HHV-7 genomic sequences 
were found in patient’s PBL �NA sample. In a plasma 
�NA sample� only genomic sequences were detected.
JCV causing PML in the patient was confirmed 
�oth in �rain �iopsy and �lood. Motor aphasia� hemi-
syndrome of the left side progressed. Patient received 
symptomatic therapy and died a month after opera-
tion� in April ���8. Post-mortem examination was not 
performed. 
DISCUSSION
PML was first descri�ed in patients with CLL and 
Hodgkin lymphoma in ��58 [6]. Association �etween 
purine nucleoside analogues and PML has �een 
explored in a systematic study of evaluation the clini-
cal characteristics of HIV-negative patients affected 
�y lymphoproliferative disorders �LP�� who develop 
PML [�]. In this study B-cell CLL was the most frequent 
underlying LP� and the most frequent treatment re-
ceived was purine analogues.
In the majority of previously descri�ed CLL cases 
PML diagnosis was confirmed with JCV detection 
in �rain �iopsy [�� 7� 8]� in some cases JCV was de-
tected in spinal fluid [�� ��]. In most of reported cases� 
similarly to the patient descri�ed �y us� PML developed 
following fludara�ine therapy [�� 8� �� ��]� therefore 
it is considered that the immunosuppressive effect 
of this therapy may cause JCV activation. Moreover� 
the case of PML development in 6�-year-old male with 
CLL after 6 months of fludara�ine therapy and without 
JCV infection is previously reported and authors sug-
gested the possi�le role of fludara�ine in producing 
PML-like lesions in patients with CLL [��]. Another 
investigation suggests that immunosuppression 
caused �y chronic lymphoproliferative malignancies 
alone may �e a factor in the development of PML and 
chemotherapy with fludara�ine may act as an addi-
tional trigger [�]� �esides some reported cases date 
�ack to the time �efore fludara�ine was accessi�le for 
treatment [��� ��].
The present case� in addition to the previously re-
ported� draws attention to the fact that the use of fluda-
ra�ine and its com�inations in CLL therapy increases 
the risk of JCV infection reactivation and development 
of serious complications like PML. Because devel-
opment of PML is tightly linked to suppression and/
or modulation of the immune system as in develop-
ment of hematological malignancies as in monoclonal 
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anti�ody treatments� further scrutiny of the course 
of JCV infection in immune cells will �e essential to our 
understanding of development of PML and identifi-
cation of new therapeutic targets [��]. The present 
case� in addition to a few previously reported� draws 
attention to the fact that the use of fludara�ine and its 
com�inations in CLL therapy increases the risk of seri-
ous infection complications like PML. 
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